{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Showing 1 - 7 of 7 results
Status:
Investigational
Source:
NCT02477020: Phase 2 Interventional Completed Schizophrenia
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
TAK-063 is a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor with IC50 of 0.30 nM; >15000-fold selectivity over other PDEs. TAK-063 is currently being evaluated in clinical trials for the treatment of schizophrenia. Phosphodiesterase 10A (PDE10A) is a cAMP/cGMP phosphodiesterase highly expressed in medium spiny neurons (MSNs) in the striatum. TAK-063 represents a promising drug for the treatment of schizophrenia with potential for superior safety and tolerability profiles.
Status:
Possibly Marketed Outside US
First approved in 2015
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Glyoxal refers to the reactive electrophilic species (RES) and is formed during different processes, e.g., lipid peroxidation, DNA oxidation. RES cause the damage of proteins and nucleotides and thus can cause different diseases in human, e.g., diabetes. Glyoxal reacting with free guanines in RNAs can be is used for chemical probing of RNA structure.
Status:
Possibly Marketed Outside US
First approved in 2015
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Glyoxal refers to the reactive electrophilic species (RES) and is formed during different processes, e.g., lipid peroxidation, DNA oxidation. RES cause the damage of proteins and nucleotides and thus can cause different diseases in human, e.g., diabetes. Glyoxal reacting with free guanines in RNAs can be is used for chemical probing of RNA structure.
